Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433988 | 1.00 | HPGD (0.69) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL9202857 | 0.83 | HPGD (0.71) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL11829949 | 0.83 | LMNA (0.72) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL28760388 | 0.82 | HPGD (0.69) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6382378 | 0.82 | HPGD (0.69) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL11627488 | 0.82 | HPGD (1.00) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL7220820 | 0.82 | HPGD (0.69) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL5321616 | 0.82 | HPGD (0.69) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL27660007 | 0.82 | HPGD (0.69) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL10352818 | 0.81 | HPGD (0.68) | HPGDALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276203-B | Method for synthesizing 2-aminobenzamide compound by ultraviolet light induction | 湖南大学 | 2023-03-31 | — | — | CN | disclosed |
| CN-114276203-A | Method for synthesizing 2-aminobenzamide compound by ultraviolet light induction | 湖南大学 | 2022-04-05 | — | — | CN | disclosed |
| US-9782407-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| EP-1848430-B1 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | Dr Reddys Laboratories Ltd (IN) | 2017-08-02 | — | — | EP | disclosed |
| EP-1981342-B1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDYS LAB LTD DR (IN) | 2016-11-30 | — | — | EP | disclosed |
| CN-105229002-A | BET protein inhibiting dihydropyridopyrazinones | Bayer Pharma AG | 2016-01-06 | — | — | CN | disclosed |
| US-20150216866-A1 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-9040558-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-05-26 | — | — | US | disclosed |
| CN-101443006-B | Novel benzylamine derivatives as CETP inhibitors | REDDY US THERAPEUTICS INC | 2012-10-10 | — | — | CN | disclosed |
| CN-101443006-A | Novel benzylamine derivatives as CETP inhibitors | REDDY US THERAPEUTICS INC (US) | 2009-05-27 | — | — | CN | disclosed |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216866-A1 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, MTTP | HPGD 2500/4885ALDH1A1 2612/4885LMNA 851/4885 |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | CETP, NPC1, LIPC | HPGD 2541/4885ALDH1A1 4060/4885LMNA 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.